esomeprazole + placebo

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vasomotor Rhinitis

Conditions

Vasomotor Rhinitis

Trial Timeline

Jun 1, 2005 โ†’ Mar 1, 2008

About esomeprazole + placebo

esomeprazole + placebo is a pre-clinical stage product being developed by AstraZeneca for Vasomotor Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00745849. Target conditions include Vasomotor Rhinitis.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (7)

NCT IDPhaseStatus
NCT01069939Phase 3Completed
NCT00660660ApprovedCompleted
NCT00542789Phase 3Completed
NCT00287339ApprovedCompleted
NCT00745849Pre-clinicalCompleted
NCT00628953Phase 2Completed
NCT00628667ApprovedCompleted

Competing Products

20 competing products in Vasomotor Rhinitis

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
77
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
52
MK-6913 + 17-ฮฒ estradiol + Placebo to MK-6913 + Placebo to 17-ฮฒ estradiol + MK-6913 25 mgMerckPhase 2
52
Erenumab + PlaceboAmgenPhase 1
32
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
84
DVS-233 SRPfizerPhase 3
76
Bazedoxifene/Conjugated EstrogenPfizerPhase 3
76
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
32
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
76
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
76
Treatment A + Treatment B + Treatment CBayerPhase 1
30
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
30
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
74
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment BBayerPhase 1
30
Elinzanetant (BAY3427080)BayerPhase 1
30
Moxifloxacin + Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
30
Elinzanetant (BAY3427080) + Dabigatran etexilateBayerPhase 1
30
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3
74
BAY3427080BayerPhase 1
30
Elinzanetant (BAY3427080) + RosuvastatinBayerPhase 1
30